Table 1 Baseline characteristics of study population according to fT3 concentration
Characteristics | Group A Low fT3 < 3.10 pmol/L (n = 9) | Group B Normal fT3 ≥ 3.10 pmol/L (n = 50) | p-value |
|---|---|---|---|
Age, years | 65.0 (58.0–78.5) | 64.5 (58.5–71.5) | 0.4047 |
Male sex, n (%) | 7 (77.8%) | 41 (82.0%) | 0.6697 |
Body mass index (kg/m2) | 20.8 (19.4–26.4) | 30.1 (26.9–33.3) | 0.0008 |
Main etiology of heart failure | |||
Ischemic | 4 (44.4%) | 25 (50.0%) | 0.7117 |
Valvular | 2 (22.2%) | 6 (12.0%) | |
Idiopathic/Other | 3 (33.3%) | 19 (38.0%) | |
Medical history, n (%) | |||
Hypertension | 8 (88.9%) | 42 (84.0%) | 1.0000 |
Dyslipidemia | 7 (77.8%) | 44 (88.0%) | 0.5946 |
Type 2 diabetes mellitus | 3 (33.3%) | 23 (46.0%) | 0.7176 |
Atrial fibrillation | 4 (44.4%) | 28 (56.0%) | 0.7187 |
Smoking | 3 (33.3%) | 18 (36.0%) | 1.0000 |
Medications prior to admission, n (%) | |||
Beta blockers | 8 (88.9%) | 46 (92.0%) | 0.5768 |
ACEI | 4 (44.4%) | 38 (76.0%) | 0.1033 |
ARB | 0 (0.0%) | 3 (6.0%) | 1.0000 |
MRA | 6 (66.7%) | 34 (68.0%) | 1.0000 |
Diuretics | 7 (77.8%) | 45 (90.0%) | 0.2880 |
Ivabradine | 3 (33.3%) | 4 (8.0%) | 0.0644 |
Digoxin | 9 (18.0%) | 2 (22.2%) | 0.6697 |
Electrotherapy prior to admission, n (%) | |||
ICD | 3 (33.3%) | 14 (28.0%) | 0.7080 |
CRT | 2 (22.2%) | 5 (10.0%) | 0.2880 |
Pacemaker | 1 (11.1%) | 3 (6.0%) | 0.4940 |
iv medication during hospitalization | |||
Iv diuretics | 8 (88.9%) | 31 (72.1%) | 0.4203 |
Iv inotropic drugs | 6 (66.7%) | 4 (8.0%) | 0.0003 |
Initial clinical findings | |||
Rales, n (%) | 7 (77.8%) | 22 (44.0%) | 0.0797 |
Peripheral edema, n (%) | 8 (88.9%) | 23 (46.0%) | 0.0274 |
Heart rate (beats/min) | 88.0 (72.5–115.0) | 80.0 (70.0–101.0) | 0.4400 |
Systolic blood pressure (mmHg) | 108.7 (±14.9) | 129.0 (±22.8) | 0.0128 |
Diastolic blood pressure (mmHg) | 73.0 (±11.17) | 82.3 (±15.2) | 0.0876 |
NYHA class | |||
III, n (%) | 3 (33.3%) | 34 (68.0%) | 0.0661 |
IV, n (%) | 6 (66.7%) | 16 (32.0%) | |